Lundgren JR, Janus C, Jensen SB, Juhl CR, Olsen LM, Christensen RM, et al
Amplifies beta-cell insulin secretion through pathways distinct from GLP-1R, modulates adipose tissue lipid handling, and appears to reduce the GI adverse-event burden associated with isolated GLP-1R agonism
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
PBH can be profoundly disabling, manifesting symptoms ranging from fatigue and headaches to severe neuroglycopenia, leading to loss of consciousness and/or seizures, sometimes necessitating hospitalization [4, 5]
In a follow-up proof-of-concept study by Aviles-Olmos et al., the longevity of motor and non-motor effects were assessed up to 24 months after the trial
Promoting high-demand drugs directly to consumers raises concerns about overprescribing and equitable access